Full-Time

Director – Special Projects BD&Ops

Confirmed live in the last 24 hours

BridgeBio

BridgeBio

501-1,000 employees

Develops medicines for genetic diseases

Compensation Overview

$215k - $265kAnnually

+ Performance Bonus + Equity

Senior, Expert

Palo Alto, CA, USA

The job is based in Palo Alto, California, and does not mention any remote work options.

Category
Procurement & Sourcing
Supply Chain Management
Operations & Logistics
Required Skills
Social Media
Data Analysis
Requirements
  • Management Consulting or Banking experience from top tier firm
  • Strategic planning, operating, and program management experience at a biotech startup or top-tier pharma
  • Life sciences undergraduate degree
  • A track record of experimenting with high-risk, high-reward initiatives
  • In-depth knowledge of social media platforms, analytics tools, and content marketing strategies
  • Exceptional written and verbal communication skills, with the ability to craft compelling narratives and pitches
  • Energetic, resourceful, and scrappy, with a “hustle harder” mindset
Responsibilities
  • Know everything being said and everyone who is talking about BridgeBio, our programs, and the patient communities that we serve.
  • Develop new story angles from across the BridgeBio portfolio based on the latest media cycles
  • Build relationships with BridgeBio evangelists
  • Develop and execute new capabilities and unconventional strategies
  • Pursue bold experimental initiatives that expand BridgeBio’s audience
  • Bet on a new communication medium, such as podcasting
  • Grow BridgeBio’s digital communications capabilities to engage new audiences
  • Re-think and lead development of an all new bridgebio.com
  • Experiment with direct digital channels to communicate 1:1 with key audiences
  • Develop scientific and financial stories
  • Directly contribute to journal papers, blog posts, and press releases about BridgeBio’s unique world view and approach to drug development
Desired Qualifications
  • Ph.D., MD, MBA, or other graduate degrees in the life sciences strongly preferred
  • Proven scientific acumen, communication skills, and an analytical mindset
  • Familiarity with influencer engagement strategies, viral content creation, or entertainment industry pitching is highly desirable

BridgeBio Pharma develops medicines specifically for genetic diseases, focusing on conditions with well-understood genetic causes. The company uses a decentralized subsidiary model, allowing each subsidiary to concentrate on therapies for specific diseases while sharing central resources. This structure enhances efficiency and enables the advancement of multiple drug programs at once. BridgeBio utilizes advancements in genome sequencing and molecular biology to identify and develop effective treatments. Their goal is to create significant therapeutic improvements by targeting diseases at their genetic source. With over 15 drug programs aimed at 20 different genetic diseases, BridgeBio aims to reduce the time it takes to bring treatments to market through a diversified approach. The company promotes a culture of independent thinking and transparency, which supports quick, data-driven decision-making.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Palo Alto, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased focus on RNA-based therapies aligns with BridgeBio's genetic disease mission.
  • Decentralized clinical trials enhance data collection, benefiting BridgeBio's model.
  • Growing personalized medicine demand supports BridgeBio's targeted genetic therapies.

What critics are saying

  • Alnylam's RNAi therapy Amvuttra poses competition to BridgeBio's ATTR-CM treatment.
  • Strategic shifts from new leadership may impact genetic disease program focus.
  • Norges Bank's investment may pressure BridgeBio for short-term financial performance.

What makes BridgeBio unique

  • BridgeBio employs a decentralized subsidiary model for efficient drug development.
  • Focuses on genetic diseases with well-understood underlying causes for targeted therapies.
  • Leverages genome sequencing and molecular biology for innovative treatment solutions.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Performance Bonus

Company Equity

Unlimited Paid Time Off

Growth & Insights and Company News

Headcount

6 month growth

5%

1 year growth

3%

2 year growth

2%
GlobeNewswire
Feb 26th, 2025
BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt

Refinancing term debt facility lowers interest expense, eliminates near-term amortization payments, and significantly extends debt maturityOffering priced...

The Manila Times
Jan 8th, 2025
BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference

PALO ALTO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) - BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced that co-founder and CEO, Neil Kumar, Ph.D., will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 13 at 7:30 am PT.

Access Market Intelligence
Dec 6th, 2024
Orsini and PANTHERx Rare Selected by BridgeBio as Pharmacy Partners for ATTRUBY

PANTHERx Rare, a leader in rare disease product patient access and support services in the United States, also announced that it was selected by BridgeBio for the distribution of Attruby (acoramidis).

PR Newswire
Nov 26th, 2024
Bridgebio Selects Pantherx® Rare Specialty Pharmacy For Distribution Of Attruby™ (Acoramidis)

PITTSBURGH, Nov. 26, 2024 /PRNewswire/ -- PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce that it was selected by BridgeBio for the distribution of Attruby™ (acoramidis), a high-affinity transthyretin (TTR) stabilizer for twice daily oral administration, approved for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM).2,5. Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR. Attruby was designed to mimic a naturally occurring "rescue mutation" of the TTR gene (T119M) that targets the root cause of ATTR-CM, destabilization of the native TTR tetramer. Through near-complete TTR stabilization, Attruby has been shown to preserve the native function of TTR as a transport protein of thyroxine and vitamin A and to demonstrate benefit on cardiovascular outcomes. "Panther is committed to providing tailored solutions for people living with rare and devastating conditions and we look forward to the partnership with BridgeBio and serving the needs of patients suffering from transthyretin amyloid cardiomyopathy," said Rob Snyder, Executive Chair, PANTHERx® Rare Pharmacy

MarketBeat
Nov 24th, 2024
Jennison Associates LLC Invests $767,000 in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Jennison Associates LLC invests $767,000 in BridgeBio Pharma, Inc. (NASDAQ:BBIO).